Jenny Bergqvist
Overview
Explore the profile of Jenny Bergqvist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tapia J, Gabrielson M, Hammarstrom M, Wengstrom Y, Bergqvist J, Tuuliainen A, et al.
BMC Health Serv Res
. 2025 Mar;
25(1):344.
PMID: 40045306
Background: Anti-estrogens are widely used to reduce recurrence in breast cancer patients. The side effects often lead to treatment non-adherence and the use of anti-hormonal treatments as primary prevention in...
2.
Hammarstrom M, Gabrielson M, Bergqvist J, Lundholm C, Crippa A, Backlund M, et al.
J Natl Cancer Inst
. 2024 Nov;
PMID: 39514025
Purpose: Monitoring metabolites of tamoxifen, such as endoxifen, has been suggested as a strategy to ascertain therapeutic effect of tamoxifen therapy but clinical guidelines are missing. Herein we aim to...
3.
Gabrielson M, Hammarstrom M, Bergqvist J, Lang K, Rosendahl A, Borgquist S, et al.
Int J Cancer
. 2024 Mar;
155(2):339-351.
PMID: 38554131
Tamoxifen prevents recurrence of breast cancer and is also approved for preventive, risk-reducing, therapy. Tamoxifen alters the breast tissue composition and decreases the mammographic density. We aimed to test if...
4.
Zeng E, He W, Sjolander A, Bergqvist J, Fang F, Czene K
J Natl Cancer Inst
. 2024 Mar;
116(6):920-928.
PMID: 38471102
Background: Many studies have examined patient-related factors affecting adjuvant hormone therapy adherence in patients with breast cancer. Our study aimed to examine associations of family-related factors with adjuvant hormone therapy...
5.
Bergqvist J, Hedskog S, Hedman C, Schultz T, Strang P
Acta Psychiatr Scand
. 2024 Feb;
149(4):313-322.
PMID: 38369614
Background: Schizophrenia and advanced cancer are complex conditions that impact life expectancy. This study aimed to examine the receipt of specialized palliative care (SPC) in patients with metastatic cancer and...
6.
Hammarstrom M, Gabrielson M, Crippa A, Discacciati A, Eklund M, Lundholm C, et al.
Br J Cancer
. 2023 May;
129(1):61-71.
PMID: 37149701
Background: Adherence to adjuvant tamoxifen therapy is suboptimal, and acceptance of tamoxifen for primary prevention is poor. Published results indicate effect of low-dose tamoxifen therapy. Using questionnaire data from a...
7.
Gabrielson M, Hammarstrom M, Backlund M, Bergqvist J, Lang K, Rosendahl A, et al.
Int J Cancer
. 2023 Jan;
152(11):2362-2372.
PMID: 36637153
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in...
8.
Zeng E, He W, Sjolander A, Bergqvist J, Czene K
Cancer Res
. 2022 Aug;
82(19):3614-3621.
PMID: 35980311
Significance: The proportion of patients with breast cancer extending adjuvant hormone therapy beyond 5 years has increased dramatically in recent years, which is associated with improved patient outcomes.
9.
Bergqvist J, Hedman C, Schultz T, Strang P
Support Care Cancer
. 2022 Jun;
30(9):7721-7730.
PMID: 35697884
Purpose: There are inequalities in cancer treatment. This study aimed to investigate whether receipt of specialized palliative care (SPC) is affected by typical female and male diagnoses (breast and prostate...
10.
Backlund M, Eriksson M, Hammarstrom M, Thoren L, Bergqvist J, Margolin S, et al.
Oncologist
. 2022 May;
27(7):e601-e603.
PMID: 35605013
Mammographic density change has proven to be a reliable proxy for tamoxifen therapy response. The primary aim of this study was to identify time to tamoxifen-induced mammographic density change. We...